Why the study?
Does oral prednisolone reduce time until ready for discharge in hospitalized children with virus-positive recurrent wheezing?
Does oral prednisolone reduce time until ready for discharge in hospitalized children with virus-positive recurrent wheezing?
Prednisolone may reduce the time to discharge in children hospitalized for recurrent wheezing specifically associated with picornavirus or enterovirus infections, though prospective trials are needed.
This is the authors' abstract. We don't add key points for this paper.
Data on the efficacy of corticosteroids on respiratory picornavirus-induced wheezing are limited. To determine whether prednisolone is effective in rhinovirus- or enterovirus-induced recurrent wheezing, we conducted a controlled trial comparing oral prednisolone (2 mg/kg/day in three divided doses for 3 days) with placebo in hospitalized wheezing children and studied post hoc virus-specific efficacy in early wheezing (<3 episodes, reported elsewhere) and in recurrent wheezing (>or=3 episodes). Virus-negative children where excluded. Our primary endpoint was the time until children were ready for discharge. Secondary endpoints included oxygen saturation and exhaled nitric oxide during hospitalization, duration of symptoms, blood eosinophil count, and impulse oscillometry 2 wk after discharge, and occurrence of relapses during the following 2 months. Virus-specific effects were analyzed with interaction analysis in a multivariate regression model. During the study period, 661 patients were hospitalized, 293 randomized, and 59 were accepted in this analysis (mean age 2.6 yr, s.d. 1.3). Prednisolone did not significantly decrease the time until ready for discharge in all patients (prednisolone vs. placebo, medians, 18 vs. 24 h, p = 0.11). However, prednisolone decreased the time until ready for discharge in children with picornavirus infection (respectively, 12 vs. 24 h, p = 0.0022) and more specifically, in children with enterovirus infection (6 vs. 35 h, p = 0.0007). In the secondary endpoints, prednisolone decreased the duration of cough and dyspnea in rhinovirus-affected children (p = 0.033 for both). Prospectively designed clinical trial is needed to test the hypothesis that prednisolone reduces symptoms in picornavirus-affected wheezing children.
Answers are grounded in this paper and cite their sources.
Does not support routine prednisolone in virus-positive wheezing; subgroup benefits leave confirmation to prospective virus-stratified trials.
No takes yet. Share an insight, caveat, or question.
Jartti et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: